Companies
Who we bring together sets us apart
Companies
Our tenants span the life science sector, including therapeutics, diagnostics, medical devices, and research tools. They learn from and support each other, often forming partnerships.
Tenant Spotlight
Tenant Spotlight on Sampling Human: Using Biology to Analyze Biology
Anyone who’s had a blood draw as a patient – in short, everyone – knows that what the doctor gets to work with is a basic count of red and white blood cells. But there’s so much information that we’re missing, which could help inform and develop much more precise treatment. Daniel Georgiev and Sampling Human want to solve this problem. Their solution: using biology to analyze biology. Read post
Tenant Spotlight
Tenant Spotlight on Regel Therapeutics: A New Approach to Gene Therapy
“I always used to enjoy science and technological innovation. For a scientist, curiosity leads to discovery, but it is a need that leads to invention. In the back of my mind, I always knew that to make a clinical product into a reality, I have to take the technology out of the lab and develop it in an industry setting. Patients and their caregivers motivated me to take this leap into entrepreneurship,” says Navneet Matharu. Read post
Tenant Spotlight
Tenant Spotlight on Coagulant, a Company Defying the Odds to Save Lives
“I think anyone who meets me understands my passion for what I’m doing,” Terry says. “I’m not here to make a business per se. I am here to impact people’s lives.” Read post
Tenant Spotlight
Tenant Spotlight on Mekonos, a Diverse Team Making Cell Therapies More Accessible
“We’ve been super fortunate to be part of Bakar Labs,” Anil says. “One of our values at Mekonos is learning every day, both on the technical and non-technical side. We’re thankful to have been part of an ecosystem where we can do both.” Read post
Tenant Spotlight
Tenant Spotlight on Via Nova Therapeutics & Antiviral Development: Seek Out Investors Whose Aims Align With Yours
“Don and I got to talking and we decided, let’s try to get these assets out of Novartis and found Via Nova. A little over a year ago, we were able to execute on a Series A, to get an initial funding of $20 million, which also enabled the in-licensing of the assets from Novartis. The four that we chose are for influenza, human rhinovirus, BK polyomavirus and adenovirus.” Two scientists without a team or a lab raised $20 million? You heard right. That funding came from Aditum Bio, an investment firm founded by former Novartis scientists who could appreciate that millions of dollars had already been invested into the R&D for these assets. Read post
Tenant Spotlight
Tenant Spotlight: Reflexion Pharmaceuticals & The Mirror World of D-Therapeutics
CEO Greg Went appreciates that our time on Earth is short. What he cares about is helping patients with medicines that work. He doesn’t have time for the ego that some scientists have tied up in the technologies they’re developing. He admits that, early on, even his company was too into itself. “What Reflexion lacked early on was the mentality of ‘why develop this technology if it’s not better than monoclonal antibodies.’ ‘Same as’: we don’t need that. We need products that are a factor of two to ten times better than the standard of care.” Read post
Tenant Spotlight
Tenant Spotlight: Valitor Aligns Its Stakeholders to Develop Biopolymer Therapeutics
“Getting the science right is hard enough, but at least I was trained to be a scientist,” says CSO and former CEO Wesley Jackson. “The skill that I had to learn the quickest was to keep all the company’s stakeholders aligned. I naively assumed that if the science was great enough, it would be sufficient to launch the business. But, instead, I found that a company can only exist because there is a team of people who have an interest in it existing.” Read post
Tenant Spotlight
Tenant Spotlight: Perlumi’s Plan to Perfect Photosynthesis
“We can’t make more land, so we need to be more efficient with it. One way to do this is to make plants fundamentally better at photosynthesis. If you make photosynthesis better, you solve a lot of problems at the same time. You increase food security, you can pull CO2 out of the atmosphere for the long term, and you can spare land for biodiversity.” Read post
Tenant Spotlight
Tenant Spotlight: Catena Biosciences and Next-Generation Protein Coupling
How can we direct therapeutics to where we want them to take effect? Often the solution lies in attaching, or conjugating, a therapy to another molecule that performs the targeting function. “We discovered a new protein conjugation process that allowed us to build things like CRISPR base editors,” says Catena CEO and co-founder Marco Lobba. “It’s not just applicable to Cas9, but also to antibodies, cell-based therapies, and several other types of new drugs.” Read post